International journal of clinical and experimental pathology最新文献

{"title":"Neuroprotective effect of sulforaphane on hyperglycemia-induced cognitive dysfunction through the Nrf2/HO-1 pathway.","authors":"Gengyin Wang, Liping Wang, Xiaohan Zhang, Zifeng Wei, Kunpeng Wang, Jinhua Wang","doi":"10.62347/CHBJ5517","DOIUrl":"10.62347/CHBJ5517","url":null,"abstract":"<p><strong>Objectives: </strong>Sulforaphane (SFN), an isothiocyanate in cruciferous plants, has been reported to be effective in treating central nervous system diseases. However, how SFN protects the central nervous system needs further study. The aim of this study was to investigate the neuroprotective effect of SFN and its possible mechanism of action.</p><p><strong>Methods: </strong>Sprague-Dawley rats were used to develop a cognitive impairment model. The Morris water maze (MWM) was used to evaluate the effect of SFN on learning and memory, and haematoxylin-eosin (H&E) staining and terminal transferase deoxyuridine nick-end labelling (TUNEL) were used to observe morphologic changes in neurons and neuronal apoptosis in the hippocampus and cortex. An oxidative stress marker kit was used to detect the content and activity of SFN, and the expressions of nuclear factor drythroid-2 related Factor 2 (Nrf2), heme oxygenase 1 (HO-1), and NAD(P)H quinone oxidoreductase 1 (NQO-1) were measured by RT-PCR.</p><p><strong>Results: </strong>SFN treatment significantly improved cognition, increased the number of neurons, and suppressed neuronal apoptosis. In addition, SFN significantly decreased the content of malondialdehyde (MDA) and enhanced the antioxidant activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in the hippocampus and cortex. Furthermore, SFN elevated the expression of Nrf-2, HO-1, and NQO-1.</p><p><strong>Conclusions: </strong>SFN ameliorated diabetes-induced cognitive dysfunction by activating the Nrf2/HO-1 pathway, providing a new perspective for SFN therapy to delay cognitive impairment in diabetes patients.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"17 12","pages":"469-476"},"PeriodicalIF":1.1,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental granular cell tumor at the ileocecal junction mimicking a lymph node metastasis in a patient with history of neuroendocrine tumor of the right colon.","authors":"Jayalakshmi N Alagar, Maria F Gonzalez","doi":"10.62347/NKKQ5944","DOIUrl":"10.62347/NKKQ5944","url":null,"abstract":"<p><p>Granular cell tumors are rare neoplasms originating from Schwann cells found in various organs. GCTs are seldom reported in the gastrointestinal tract. Pre-operative detection and diagnosis of colonic GCTs is challenging since the tumors are mainly asymptomatic, small, slow-growing, and submucosal. Most of these tumors are benign in histopathology and behavior. Recently, there has been greater insight into the varying presentations and behaviors of colonic GCTs with atypical histopathologic features. To contribute, we describe a GCT (2.3 cm) at the ileocecal junction found incidentally during follow-up for an excised ileal neuroendocrine tumor in a 65-year-old woman. Our GCT had an unusual focal atypia and infiltrative behavior into the pericolonic adipose tissue without metastasizing to the lymph nodes. These features are important since GCTs have a propensity for local recurrence if incompletely excised, which could have been easily missed. Even though GCTs with atypical features have low rates of recurrence and metastasis, they require close and careful attention in the absence of specific management guidelines due to potential aggressive behavior.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"17 12","pages":"487-491"},"PeriodicalIF":1.1,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TPM3::NTRK1-rearranged uterine sarcoma: case report and literature review.","authors":"Yalan Yang, Lei Li","doi":"10.62347/PTTF8718","DOIUrl":"10.62347/PTTF8718","url":null,"abstract":"<p><p>Neurotrophic tyrosine kinase receptor (NTRK)-rearranged uterine sarcoma is a rare type of uterine sarcoma. This paper presents a case of a 49-year-old female who was admitted to the hospital due to lower abdominal pain and subsequently diagnosed with tropomyosin 3 (TPM3)::NTRK1-rearranged uterine sarcoma. To our knowledge, TPM3::NTRK1-rearranged sarcomas almost always occur in the cervix, and this is a novel case of uterine corpus occurrence. The patient received chemotherapy and radiotherapy after surgery. No recurrence or metastasis was observed after 9 months of treatment. Moreover, all reported clinicopathological features, treatment methods, and prognoses of NTRK-rearranged uterine sarcoma patients are reviewed herein.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"17 12","pages":"477-486"},"PeriodicalIF":1.1,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of atezolizumab combined with bevacizumab, arterial chemoembolization, and hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma: a meta-analysis.","authors":"Xinlin Yu, Ran Cui, Yan Jiang, Ping Guo","doi":"10.62347/MBQJ8679","DOIUrl":"10.62347/MBQJ8679","url":null,"abstract":"<p><strong>Objective: </strong>Although the combination of atezolizumab and bevacizumab (A+B) shows promise for advanced hepatocellular carcinoma (HCC), its response rate is still inadequate. Previous studies indicate that the integration of FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) with transarterial chemoembolization (TACE) is advantageous for the management of HCC. This meta-analysis aims to assess the safety and efficacy of the A+B+TACE or HAIC therapy protocol in patients with advanced HCC.</p><p><strong>Method: </strong>We collected pertinent studies from databases such as PubMed, Cochrane Library, Web of Science, and Embase, all published prior to August 1, 2024. We used Stata MP 14.0 software for data analysis, incorporating data extraction and quality assessment procedures.</p><p><strong>Results: </strong>Data synthesis employed a fixed-effects model in certain contexts and a random-effects model where significant variability was present. A total of 405 patients were involved over ten trials. The overall objective response rate (ORR) was 57.2% (95% CI, 46.9-67.6%), and the disease control rate (DCR) was 85.9% (95% CI, 82.0-89.7%), as determined by the modified response assessment criteria in solid tumors (mRECIST). The rates for complete response (CR) and partial response (PR) were 10.8% (95% CI, 5.0-16.6%) and 45.5% (95% CI, 38.0-53.0%), respectively. The median progression-free survival (mPFS) was 10.9 months, with a 95% confidence interval (CI) of 8.0 to 13.8. 91.0% (95% CI: 84.9-97.1%) of patients experienced adverse events (AEs) of any severity during therapy, with 24.8% (95% CI: 8.8-40.9%) reporting AEs of grade 3 or higher.</p><p><strong>Conclusion: </strong>The A+B+TACE-HAIC therapy demonstrates promising efficacy and tolerance for the management of advanced HCC.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"17 12","pages":"444-457"},"PeriodicalIF":1.1,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bmi-1 plays an important role in preventing bone aging by regulating the bone microenvironment.","authors":"Li Liu, Yuanqing Huang","doi":"10.62347/DIIJ2884","DOIUrl":"10.62347/DIIJ2884","url":null,"abstract":"<p><strong>Background: </strong>B-cell specific Moloney MLV insertion site-1 (Bmi-1) belongs to the polycomb group (PcG) gene and is a transcriptional suppressor to maintain appropriate gene expression patterns during development. To investigate whether the Bmi-1 gene has a corrective effect on bone senescence induced in Bmi-1^-/- mice through regulating the bone microenvironment.</p><p><strong>Methods: </strong>Littermate heterozygous male and female mice (Bmi-1^+/-) were used in this study. Related experiments were performed in wild type mice (10 mice, WT group) and Bmi-1 knock out mice (10 mice, BKO group) for analysis of phenotype, skeletal radiography, micro-computed tomography, histology, immunohistochemical staining, western blot analysis, and detection of ROS levels.</p><p><strong>Results: </strong>Our results indicated that the Bmi-1 gene could proportionally rescued mice suffering from bone aging induced by Bmi-1 gene defects. Bmi-1 plays an anti-aging effect in bone through multiple aspects, such as increasing osteoblast bone formation and decreascing osteoclast bone absorption, stimulating proliferation, reducing apoptosis, inhibiting reactive oxygen species (ROS) and delaying DNA damage.</p><p><strong>Conclusions: </strong>Our results suggested that Bmi-1 may play a fundamental and important role in correcting bone senescence in BKO mice. At the same time, it may provide theoretical basis for the clinical application of Bmi-1 in anti-aging in bone.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"17 12","pages":"458-468"},"PeriodicalIF":1.1,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic administration of PEPITEM in experimental autoimmune encephalomyelitis delays disease onset, inhibits leukocyte infiltration, and alleviates severity.","authors":"Mohammed Alassiri, Fahd Al Sufiani, Mohammed Aljohi, Asma Alanazi, Aiman S Alhazmi, Bahauddeen M Alrfaei, Hasan Alnakhli, Mohammed Alasseiri, Nora Alorf, Mashan L Abdullah","doi":"10.62347/LTAO2386","DOIUrl":"10.62347/LTAO2386","url":null,"abstract":"<p><strong>Background: </strong>Multiple sclerosis (MS) is a chronic, immune-mediated neurological disorder in which the immune system mistakenly attacks the myelin sheath, affecting the communication between the brain and the rest of the body.</p><p><strong>Objective: </strong>This study investigated the prophylactic use of peptide inhibitor of trans-endothelial migration (PEPITEM), a novel peptide, in alleviating experimental autoimmune encephalomyelitis (EAE), a mouse model for Multiple Sclerosis (MS).</p><p><strong>Methods: </strong>Female C57BL/6 female mice were assigned to the control, untreated EAE, or PEPITEM group. EAE was induced in mice in the untreated EAE and PEPITEM groups through immunization by injecting an emulsion containing myelin oligodendrocyte glycoprotein 35-55 in complete Freund's adjuvant. Mice in these groups subsequently received PEPITEM or scramble peptide injections daily for 21 days. Then, all mice were euthanized to obtain samples for histologic and immunohistochemical analyses of central nervous system lymphocytic infiltrate. Levels of biomarkers, including myelin basic protein, microtubule-associated protein 2 (MAP-2), interleukin-17 (IL-17), and forkhead box P3 (Foxp3), were evaluated in both serum and spinal cord lysates using western blotting and enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>In the PEPITEM group, EAE onset was significantly delayed and disease severity was reduced compared to the untreated EAE group. Analysis of spinal cord tissues revealed a marked reduction in inflammatory cell infiltration following PEPITEM administration. Furthermore, PEPITEM treatment led to significantly reduced IL-17 and Foxp3 levels, highlighting its potential in mitigating inflammatory responses.</p><p><strong>Conclusion: </strong>PEPITEM has potent prophylactic potential against MS, providing a robust foundation for further exploration.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"17 12","pages":"492-505"},"PeriodicalIF":1.1,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activation of cGAS confers PARP inhibitor resistance in ovarian cancer via the TBK1-IRF3 axis.","authors":"Hongxia Guo, Rui Lu, Shuibin Yuan, Falin Xu, Chunyan Huang, Jingzhi Li, Wuqiong Ge, Yue Geng, Yan Zhang, Qiong Liu, Peng Wang, Wenqing Li","doi":"10.62347/XOPN6908","DOIUrl":"10.62347/XOPN6908","url":null,"abstract":"<p><strong>Objectives: </strong>Ovarian cancer is a gynecologic tumor with the highest mortality rate worldwide. Nonetheless, chemoresistance remains a significant obstacle in treating ovarian cancer. PARP inhibitors (PARPis) are effective drugs approved for maintenance therapy in ovarian cancer. However, the development of natural or acquired resistance to PARPis poses a major challenge for ovarian cancer treatment.</p><p><strong>Methods: </strong>Public database analysis of cGAS expression in relation to PARPi resistance. cCK-8 assay was used to determine cell survival. qPCR assay with Western Blot was implemented to determine gene expression and protein activation status.</p><p><strong>Results: </strong>Analysis of public databases revealed significantly higher cGAS expression in Olaparib-resistant cells and in recurrent ovarian tumors. Furthermore, high cGAS expression significantly promoted Olaparib tolerance in ovarian cancer cells. Our findings demonstrate that Olaparib treatment induces activation of the TBK1-IRF3 signaling axis downstream of cGAS, leading to the production of type I interferon. This, in turn, activates NF-κB and IL-6-STAT3 signaling, contributing to inflammation and PARPi resistance. Consequently, targeting cGAS effectively counteracts Olaparib resistance and enhances its efficacy in suppressing cancer cell growth, ultimately leading to cell death.</p><p><strong>Conclusions: </strong>Our study highlights the crucial function of cGAS signaling in mediating PARPi resistance in ovarian cancer cells. These findings provide valuable novel therapeutic strategies targeting cGAS to improve the efficacy of PARPi-based treatments for ovarian cancer.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"17 11","pages":"429-438"},"PeriodicalIF":1.1,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer.","authors":"Bin Kong, Zhi-Dong Lv, Yu Wang, Li-Ying Jin, Lei Ding, Zhao-Chuan Yang","doi":"10.62347/PBKP4984","DOIUrl":"https://doi.org/10.62347/PBKP4984","url":null,"abstract":"<p><p>[This corrects the article on p. 11076 in vol. 8, PMID: 26617826.].</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"17 11","pages":"439-441"},"PeriodicalIF":1.1,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic anticancer activity of resveratrol with cisplatin and carboplatin in A549 lung adenocarcinoma cells.","authors":"Kareena Moar, Mettle Brahma, Anuja Pant, Mulaka Maruthi, Pawan Kumar Maurya","doi":"10.62347/RYSQ1416","DOIUrl":"10.62347/RYSQ1416","url":null,"abstract":"<p><strong>Background: </strong>This study looked at the efficacy of combining the phytochemical resveratrol with the anticancer drugs cisplatin and carboplatin on lung adenocarcinoma cell lines.</p><p><strong>Materials and methods: </strong>We used MTT assay and generation of Reactive Oxygen Species levels using molecular fluorogenic probe 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) to investigate the effects of resveratrol in combination with cisplatin and carboplatin on the proliferation and viability of cells and levels of reactive oxygen species (ROS).</p><p><strong>Results: </strong>Resveratrol has an anti-proliferative effect on A549 lung cancer cells, inhibiting cell proliferation in a dose and time-dependent manner. Resveratrol in conjunction with cisplatin and carboplatin inhibited cell proliferation synergistically. The combination therapy of cisplatin and carboplatin with Resveratrol showed enhanced growth inhibition of lung cancer cells in <i>in-vitro</i> with IC50 values of 15.09 ± 0.71 µM and IC50 values of 21.72 ± 1.9 µM, respectively. The present investigation also revealed the significant dose-dependent ROS generation in A549 cells by cisplatin, carboplatin, and their combination with resveratrol. Carboplatin treatment in combination with Resveratrol induced a higher generation of ROS (3.4-fold) when compared to carboplatin treatment (2.4-fold) at the highest concentration.</p><p><strong>Conclusions: </strong>Our findings offered a basis for further research for assessing the potential of Resveratrol as a therapeutic agent to treat lung adenocarcinoma and whether it can be used as an adjuvant with drugs like cisplatin and carboplatin for improving their efficacies. However, the underlying processes of cell inhibition and cell death should be thoroughly investigated.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"17 11","pages":"411-420"},"PeriodicalIF":1.1,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between EPCAM upregulation and clinicopathological parameters and outcomes of breast cancer.","authors":"Nahid Nafissi, Saeed Azad Armaki, Ebrahim Babaee, Pegah Babaheidarian, Elaheh Safari, Soheila Sayad, Samine Saghafinia, Masoumeh Safaee","doi":"10.62347/EGXS1506","DOIUrl":"10.62347/EGXS1506","url":null,"abstract":"<p><strong>Introduction: </strong>EpCAM (epithelial cell adhesion molecule) protein expression was detected in 45 to 90% of breast cancers in different studies, and high expression levels were associated with poor outcomes in several retrospective analyses. This study aims to investigate the relationship between EpCAM and clinicopathological parameters and survival in breast cancer.</p><p><strong>Methodology: </strong>This study was conducted as a Quasi-Experimental Cohort Study to explore 100 breast cancer patients. After the surgical excision of breast cancer, pathology blocks were deparaffinized and subjected to IHC (immunohistochemistry) for EpCAM examination. Using a Roche VENTANA Benchmark GX automated staining instrument and a well-established IHC staining protocol, the expression of EpCAM in breast cancer tissue was assessed. Independent sample T-test and Chi squared and Logistic Regression test with STATA version 17 software were used for data analysis.</p><p><strong>Results: </strong>The difference in the distribution of the negative state of biomarkers (ER = estrogen receptor, PR = Progesterone receptor) and EPCAM positive group was significant (<i>P</i>-value = 0.002) (<i>P</i>-value = 0.006). A statistically insignificant distinction was observed in the distribution of the HER2 (human epidermal growth factor receptor) and EPCAM groups (<i>P</i>-value = 0.198). With 30.95% of those in the EPCAM-positive cohort experienced metastasis or recurrence. ER+ and PR+ decreased the chance of EPCAM positive by 0.25 and 0.29, respectively. HER2+ and Basal like breast cancer increase the chances of EPCAM being positive by 1.9 and 2.08, respectively. Basal like breast cancer increases the odds of EpCAM positive 2.19 times. Similarly, N2 and stage 3 increase the odds of EpCAM positive by 1.95 and 0.5 times, respectively.</p><p><strong>Conclusion: </strong>We found that Basal like breast cancer, HER2+, and stage 3 increase the chance of EpCAM positivity. It seems that EPCAM positive cancer has more chance for recurrence and metastasis.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"17 11","pages":"421-428"},"PeriodicalIF":1.1,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}